Lurasidone Tablet Granulation Segmentation for Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lurasidone's poor water solubility complicates the preparation of pharmaceutical compositions with an equivalent dissolution profile, and existing granulation techniques do not effectively address segregation issues and manufacturing costs for oral formulations.
Innovation Solution
The development of an oral pharmaceutical composition using the top spray granulation technique with lurasidone and pharmaceutically acceptable excipients like microcrystalline cellulose, binders, disintegrants, and lubricants, optimizing the ratio and proportion of ingredients to enhance drug release and manufacturing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional granulation techniques are used for lurasidone formulation, then manufacturing process is simpler, but drug dissolution profile is inferior and segregation occurs
Solution Approach 1:
The formulation is segmented into granulated and non-granulated portions. Lurasidone is selectively granulated with specific excipients (microcrystalline cellulose, starch, binder solution) to form granules with controlled size distribution (40-60 mesh), while other excipients remain non-granulated. This segmentation prevents segregation and optimizes dissolution by creating distinct functional zones in the tablet.
Solution Approach 2:
Different regions of the formulation receive different treatments: lurasidone-containing granules provide localized high-density zones for controlled dissolution, while non-granulated excipients provide porosity and disintegration. The granules have specific surface area and pore structure characteristics that differ from the bulk material, creating local quality variations that enhance overall performance.
2Manufacturing precision
If lurasidone is granulated to improve dissolution, then drug release is enhanced, but manufacturing cost increases
Solution Approach 1:
Instead of granulating the entire formulation, only the lurasidone-containing portion is granulated (partial action). This reduces the amount of binder solution, energy, and equipment capacity required compared to full formulation granulation, while still achieving the dissolution enhancement needed for the active ingredient.
Solution Approach 2:
The granulation process parameters are optimized for cost-effectiveness: using readily available excipients (microcrystalline cellulose, starch), controlling granule size within standard mesh ranges (40-60 mesh), and using conventional binder solutions. These parameter choices balance performance improvement with manufacturing economy.
3Device complexity
If ingredients are simply blended to reduce complexity, then manufacturing is easier, but active ingredient segregation occurs
Solution Approach 1:
Lurasidone is preliminary granulated with selected excipients before final blending. This preliminary action creates granules with optimized physical properties (size, density, surface area) that are more compatible with the remaining non-granulated excipients, preventing segregation during subsequent handling and compression.
Solution Approach 2:
The formulation creates a composite structure where granulated lurasidone cores are surrounded by non-granulated excipients. This composite approach combines materials with different physical properties (granulated vs. non-granulated, different densities, different surface areas) in a way that maintains blend uniformity and prevents segregation.
Data Source
AI summary
The present invention relates to an oral pharmaceutical composition, particularly a tablet, comprising an active ingredient lurasidone or its pharmaceutically acceptable salt(s) or solvate(s) thereof and one or more pharmaceutical excipient(s); and a process for its preparation.